Genovis AB (publ.) (GENO)
Free
No email, no account, no signup.
Pulling latest news for Genovis AB (publ.)…
Bull
Bear
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report – Signal
NEUTRAL
Sentiment
8/10
Risk
4/10
Get full analysis with Bull/Bear case, catalysts, and risk analysis
Buy express analysis –
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Sentiment is neutral-to-positive and slightly improved on the MGI Tech collaboration (potentially broader commercial reach for SEQURNA), while the CFO change adds some near-term uncertainty.
Exchange
Nasdaq First North Growth Market
Type
Biotech
Sector
Life science tools and enzyme technology
Market Cap
$110M
Market sentiment
Sentiment is neutral-to-positive and slightly improved on the MGI Tech collaboration (potentially broader commercial reach for SEQURNA), while the CFO change adds some near-term uncertainty.
Why NEUTRAL ?
- **Review/wait** for Q1 2026 to assess actual growth, margins, and integration impact
- **Positive**: profitability and strong cash reduce financing risk
- **Uncertainty**: speed of monetization from new deals/Sequrna and how much is already priced in
- Hold existing position; consider adding after a strong Q1 report.
Recent News
- On 1 June 2026, Genovis announced the acquisition of KPL ApS for DKK 30.5m (partly cash and partly via 1,395,587 new shares at SEK 20.03) plus a sales-based earn-out payable in 2030. Q1 2026 (28 April) reported net sales of SEK 33.5m (+4% reported, +17% FX-adjusted), EBITDA of SEK 9.5m (28.4% margin) and strong operating cash flow. Next report is Q2 on 23 July 2026.
Bull case
- **Q1 report (28 Apr 2026)** may confirm continued growth and margin strength
- **Delivery/impact of a larger order (~EUR 1m)** could support revenue/cash flow in early 2026
- **News momentum** from partnerships/licensing may support valuation
Unlock to read more →
Bear case
- **FX headwinds (strong SEK)** can pressure reported revenue
- **Timing risk**: partnerships/licensing may have limited Q1 financial impact
- **Quarterly lumpiness** in orders can lead to disappointment
Unlock to read more →
Catalysts
23 Jul 2026 — Delivery of ~EUR 1m order
Dilution Risk
Assessment: Low
Order analysis – $4.99 $1.25
Save hours of research. $4.99 $1.25.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Want to read the full analysis?
Order a fresh analysis of Genovis AB (publ.) – ready in your inbox in 5–15 minutes.
- Signal + risk + sentiment
- Bull/Bear case + triggers
- Catalysts with dates
- Saved as a webpage in your account
- Ready in 5–15 min (email when ready)
Full analysis at introductory pricing — 7-day money-back guarantee.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Fact-based analysis
Updated weekly
No commitment period
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.